AURINIA PHARMACEUTICALS ($NASDAQ:AUPH) reported revenue of USD 41.5 million for the second quarter of Fiscal Year 2023, ending on June 30 2023, representing an increase of 47.2% compared to the same period in the previous year. Net income for Q2 2023 was USD -11.5 million, down from -35.5 million in the same quarter of the prior year.
On Thursday, AURINIA PHARMACEUTICALS reported their Q2 FY 2023 earnings results, with their stock opening the day at $10.4, and closing at $10.6, an increase of 4.2% from the previous closing price of 10.1. This positive news from the pharmaceutical company is further evidence that their continued investments in research and development are paying off. The company’s continued focus on R&D and innovation should enable them to continue to generate strong returns for their shareholders in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Aurinia Pharmaceuticals Intrinsic Value Calculation
At GoodWhale, we conducted an analysis of AURINIA PHARMACEUTICALS‘s financials. Our proprietary Valuation Line analysis calculated the intrinsic value of AURINIA PHARMACEUTICALS share to be around $28.0. This is significantly higher than the current trading price of $10.6, which means it is undervalued by 62.1%. This presents an attractive opportunity for investors to purchase AURINIA PHARMACEUTICALS stock at a discounted price. More…
Risk Rating Analysis
Star Chart Analysis
The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.
– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)
Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.
Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.
MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
Aurinia Pharmaceuticals reported strong second quarter results for Fiscal Year 2023, with total revenue increasing 47.2% year-over-year to $41.5 million. Despite posting a net income of $-11.5 million for the quarter, this was an improvement from the same quarter last year. Investors reacted positively to the news, sending the stock price up on the same day.
Overall, Aurinia Pharmaceuticals seems to be making progress in terms of their financial performance. The company should be watched closely for further updates on revenue and profits that could indicate a potential long-term investment opportunity.